These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 36642232)

  • 41. Association between voriconazole exposure and Sequential Organ Failure Assessment (SOFA) score in critically ill patients.
    Bienvenu AL; Pradat P; Plesa A; Leclerc V; Piriou V; Fellahi JL; Argaud L; Rimmelé T; Menotti J; Aubrun F; Richard JC; Gagnieu MC; Parant F; Chidiac C; Leboucher G; Tod M; Goutelle S
    PLoS One; 2021; 16(11):e0260656. PubMed ID: 34818379
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Population pharmacokinetics, safety and dosing optimization of voriconazole in patients with liver dysfunction: A prospective observational study.
    Tang D; Yan M; Song BL; Zhao YC; Xiao YW; Wang F; Liang W; Zhang BK; Chen XJ; Zou JJ; Tian Y; Wang WL; Jiang YF; Gong GZ; Zhang M; Xiang DX
    Br J Clin Pharmacol; 2021 Apr; 87(4):1890-1902. PubMed ID: 33010043
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Investigation of Saliva as an Alternative to Plasma Monitoring of Voriconazole.
    Vanstraelen K; Maertens J; Augustijns P; Lagrou K; de Loor H; Mols R; Annaert P; Malfroot A; Spriet I
    Clin Pharmacokinet; 2015 Nov; 54(11):1151-60. PubMed ID: 25910879
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Voriconazole-related severe adverse events: clinical application of therapeutic drug monitoring in Korean patients.
    Kim SH; Yim DS; Choi SM; Kwon JC; Han S; Lee DG; Park C; Kwon EY; Park SH; Choi JH; Yoo JH
    Int J Infect Dis; 2011 Nov; 15(11):e753-8. PubMed ID: 21831685
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical experience of the use of voriconazole, caspofungin or the combination in primary and salvage therapy of invasive aspergillosis in haematological malignancies.
    Raad II; Zakhem AE; Helou GE; Jiang Y; Kontoyiannis DP; Hachem R
    Int J Antimicrob Agents; 2015 Mar; 45(3):283-8. PubMed ID: 25455847
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The Investigation and Prediction of Voriconazole-Associated Hepatotoxicity under Therapeutic Drug Monitoring
    Ma J; Wang Y; Ma S; Li J
    Annu Int Conf IEEE Eng Med Biol Soc; 2023 Jul; 2023():1-4. PubMed ID: 38082975
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy and safety of isavuconazole against deep-seated mycoses: A phase 3, randomized, open-label study in Japan.
    Kohno S; Izumikawa K; Takazono T; Miyazaki T; Yoshida M; Kamei K; Ogawa K; Taniguchi S; Akashi K; Tateda K; Mukae H; Miyazaki Y; Okada F; Kanda Y; Kakeya H; Suzuki J; Kimura SI; Kishida M; Matsuda M; Niki Y
    J Infect Chemother; 2023 Feb; 29(2):163-170. PubMed ID: 36307059
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Evaluation dosing intravenous voriconazole three times a day vs twice daily for the treatment of invasive aspergillosis in immunocompromised children: therapeutic drugs monitoring and safety].
    Barraza M; Torres JP; Coria P; Miranda R; Palma J; García P; Azócar M; Santolaya ME; Morales J
    Rev Chilena Infectol; 2022 Feb; 39(1):14-19. PubMed ID: 35735275
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Optimal timing for therapeutic drug monitoring of voriconazole to prevent adverse effects in Japanese patients.
    Hanai Y; Ueda T; Hamada Y; Oda K; Takahashi Y; Nakajima K; Miyazaki Y; Kiriyama M; Uekusa S; Matsuo K; Matsumoto K; Kimura T; Takesue Y
    Mycoses; 2023 Dec; 66(12):1035-1044. PubMed ID: 37584173
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Contribution of voriconazole N-oxide plasma concentration measurements to voriconazole therapeutic drug monitoring in patients with invasive fungal infection.
    Boglione-Kerrien C; Morcet J; Scailteux LM; Bénézit F; Camus C; Mear JB; Gangneux JP; Bellissant E; Tron C; Verdier MC; Lemaitre F
    Mycoses; 2023 May; 66(5):396-404. PubMed ID: 36698317
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of proton pump inhibitor on plasma voriconazole concentration in Thai patients.
    Chayakulkeeree M; Poovipirom N; Siengwattana P; Maneerattanaporn M
    J Med Assoc Thai; 2015 Mar; 98(3):232-7. PubMed ID: 25920292
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy and safety of voriconazole in the treatment of invasive pulmonary aspergillosis in patients with liver failure: study protocol for a randomized controlled clinical trial.
    Yu X; Xu L; Zheng J; Lei Z; Pang Y; Li X; Zhu J; Liu J
    Trials; 2023 Dec; 24(1):811. PubMed ID: 38105213
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Voriconazole pharmacokinetic variability in cystic fibrosis lung transplant patients.
    Berge M; Guillemain R; Boussaud V; Pham MH; Chevalier P; Batisse A; Amrein C; Dannaoui E; Loriot MA; Lillo-Le Louet A; Billaud EM
    Transpl Infect Dis; 2009 Jun; 11(3):211-9. PubMed ID: 19302272
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Posaconazole therapeutic drug monitoring in clinical practice and longitudinal analysis of the effect of routine laboratory measurements on posaconazole concentrations.
    Märtson AG; Veringa A; van den Heuvel ER; Bakker M; Touw DJ; van der Werf TS; Span LFR; Alffenaar JC
    Mycoses; 2019 Aug; 62(8):698-705. PubMed ID: 31145490
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Impact of the CYP2C19 genotype on voriconazole exposure in adults with invasive fungal infections.
    Hamadeh IS; Klinker KP; Borgert SJ; Richards AI; Li W; Mangal N; Hiemenz JW; Schmidt S; Langaee TY; Peloquin CA; Johnson JA; Cavallari LH
    Pharmacogenet Genomics; 2017 May; 27(5):190-196. PubMed ID: 28306618
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Research of optimal dosing regimens and therapeutic drug monitoring for vancomycin by clinical pharmacists: analysis of 7-year data].
    Xu G; Chen E; Mao E; Che Z; He J
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2018 Jul; 30(7):640-645. PubMed ID: 30045790
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cost-effectiveness analysis of isavuconazole versus voriconazole for the treatment of patients with possible invasive aspergillosis in Sweden.
    Floros L; Kuessner D; Posthumus J; Bagshaw E; Sjölin J
    BMC Infect Dis; 2019 Feb; 19(1):134. PubMed ID: 30744563
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Impact of CYP2C19 Genotype and Drug Interactions on Voriconazole Plasma Concentrations: A Spain Pharmacogenetic-Pharmacokinetic Prospective Multicenter Study.
    Blanco-Dorado S; Maroñas O; Latorre-Pellicer A; Rodríguez Jato MT; López-Vizcaíno A; Gómez Márquez A; Bardán García B; Belles Medall D; Barbeito Castiñeiras G; Pérez Del Molino Bernal ML; Campos-Toimil M; Otero Espinar F; Blanco Hortas A; Durán Piñeiro G; Zarra Ferro I; Carracedo Á; Lamas MJ; Fernández-Ferreiro A
    Pharmacotherapy; 2020 Jan; 40(1):17-25. PubMed ID: 31782536
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparing the safety and efficacy of voriconazole versus posaconazole in the prevention of invasive fungal infections in high-risk patients with hematological malignancies.
    Hachem R; Assaf A; Numan Y; Shah P; Jiang Y; Chaftari AM; Raad II
    Int J Antimicrob Agents; 2017 Sep; 50(3):384-388. PubMed ID: 28694233
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.